Join
Live feed
·
PRReleasevia Quantisnow
Vigil Neuroscience Inc. logo

Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP

ByQuantisnow·Wall Street's wire, on your screen.
VIGL· Vigil Neuroscience Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VIGL (Vigil Neuroscience Inc.) and more on Quantisnow.

Vigil Neuroscience Announces Interim Topline Results from its Ongoing Phase 1 Clinical Trial Evaluating VGL101 in Healthy Volunteers Supporting Phase 2 Initiation in ALSP | Quantisnow